VECT vs. NAMS, PTGX, VERA, CGON, BEAM, MIRM, CNTA, IDYA, MESO, and AGIO
Should you be buying VectivBio stock or one of its competitors? The main competitors of VectivBio include NewAmsterdam Pharma (NAMS), Protagonist Therapeutics (PTGX), Vera Therapeutics (VERA), CG Oncology (CGON), Beam Therapeutics (BEAM), Mirum Pharmaceuticals (MIRM), Centessa Pharmaceuticals (CNTA), IDEAYA Biosciences (IDYA), Mesoblast (MESO), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry.
VectivBio vs.
NewAmsterdam Pharma (NASDAQ:NAMS) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 9.7% of VectivBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
NewAmsterdam Pharma currently has a consensus price target of $39.80, suggesting a potential upside of 70.09%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than VectivBio.
NewAmsterdam Pharma received 13 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 43.48% of users gave VectivBio an outperform vote.
In the previous week, NewAmsterdam Pharma had 4 more articles in the media than VectivBio. MarketBeat recorded 5 mentions for NewAmsterdam Pharma and 1 mentions for VectivBio. NewAmsterdam Pharma's average media sentiment score of 0.85 beat VectivBio's score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.
VectivBio has higher revenue and earnings than NewAmsterdam Pharma.
Summary
NewAmsterdam Pharma beats VectivBio on 9 of the 11 factors compared between the two stocks.
Get VectivBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for VECT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VectivBio Competitors List
Related Companies and Tools
This page (NASDAQ:VECT) was last updated on 1/21/2025 by MarketBeat.com Staff
